GPRC5D PET/CT scan for plasma cell disorders
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses a special PET/CT scan to look for a protein called GPRC5D in people with plasma cell disorders (like multiple myeloma). The scan might help doctors see where the disease is in the body. Healthy volunteers can also join to help compare results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a plasma cell disorder (like multiple myeloma) or you are a healthy volunteer.
- You have had recent lab tests (within the last week) if you have a plasma cell disorder.
- You are able to have a PET/CT scan.
- You do not have any other active cancer that is considered significant by the study doctor.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent that may help doctors see multiple myeloma more clearly. It uses a special radioactive tracer that targets a protein found on myeloma cells, which could improve diagnosis and monitoring of the disease.
This study uses advanced imaging (PET-CT scans) to help doctors better see multiple myeloma in patients who are about to receive CAR T-cell therapy. The goal is to improve how doctors detect and monitor the cancer using a newer type of scan.
This study uses a special PET/MR scan with a tracer called 68Ga-Pentixafor to see if it can better find lymphoma and multiple myeloma spots in the body. It may help doctors get clearer pictures than standard scans.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
This trial tests a new type of cell therapy called GPRC5D CAR-T for people with multiple myeloma or other plasma cell cancers that have come back or stopped responding to treatment. The therapy uses your own immune cells to attack cancer cells that have a specific marker called GPRC5D, aiming to stop the disease from growing.
Hear when a new Plasma Cell Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.